Drug Database
RE

recombinant human growth hormone (Ansomone)

✓ Approved

Anhui Anke Biotechnology · GHR · Recombinant Proteins

What is recombinant human growth hormone?

recombinant human growth hormone is a recombinant proteins developed by Anhui Anke Biotechnology. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesAnsomone
CompanyAnhui Anke Biotechnology
Drug ClassRecombinant Proteins, Polypeptide
Molecular TargetGHR
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Anhui Anke Biotechnology

Mechanism of Action

Molecular Targets

recombinant human growth hormone acts on 1 molecular target:

GHRgrowth hormone receptor (GHBP, GHIP)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

recombinant human growth hormone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Endocrine disordersGrowth hormone deficiency✓ Approved

Related Research Articles

PubMedCureus2026-09-20

Thyroid Hormone Levels and Its Co-relation With Human Chorionic Gonadotropin in Patients With Molar Pregnancy.

Singh Priyadarsini P, Behera Swayamprava S, Patra Lipsa L, Behuria Sasmita S et al.

Introduction Gestational trophoblastic disease (GTD) is characterized by abnormal trophoblastic proliferation, with hydatidiform mole being its most common form. Markedly elevated serum human chorionic gonadotropin (hCG) concentrations in molar pregnancy can stimulate thyroid-stimulating hormone receptors, resulting in thyroid dysfunction. This study aimed to evaluate thyroid hormone levels and their correlation with serum β-human chorionic gonadotropin (β-hCG) concentrations in patients with molar pregnancy and to compare thyroid function between complete and partial hydatidiform mole. Materials and methods This prospective observational study was conducted in the Department of Obstetrics and Gynaecology, Srirama Chandra Bhanja (SCB) Medical College and Hospital, Cuttack, Odisha, India, from January 2022 to December 2023. Eighty-eight women with histopathologically confirmed hydatidiform mole were included after excluding 26 patients who had received initial treatment elsewhere and were referred exclusively for oncological management. Serum β-hCG, thyroid-stimulating hormone (TSH), free triiodothyronine (free T3), free thyroxine (free T4), total triiodothyronine (total T3), and total thyroxine (total T4) were measured before uterine evacuation. Thyroid hormone profiles were compared between complete and partial mole, and correlations between serum β-hCG and thyroid hormone parameters were analyzed using Pearson's correlation coefficient. Results Among 15,844 deliveries, 88 women with histopathologically confirmed hydatidiform mole were analyzed, yielding a hospital-based frequency of 5.5 per 1,000 deliveries. Complete mole constituted 57 (64.8%) cases and partial mole 31 (35.2%). Patients with complete mole had significantly lower TSH (0.82±0.71 vs. 1.96±0.82 µIU/mL; p<0.001) and significantly higher free T3, free T4, total T3, total T4, and β-hCG levels than those with partial mole (all p<0.001). Serum β-hCG demonstrated a significant negative correlation with TSH (r=-0.61; p<0.001) and positive correlations with free T3 (r=0.73), free T4 (r=0.69), total T3 (r=0.65), and total T4 (r=0.67) (all p<0.001). Conclusion Complete hydatidiform mole was associated with significantly higher serum β-hCG concentrations and more pronounced thyroid dysfunction than partial hydatidiform mole. Serum β-hCG concentrations demonstrated a significant negative correlation with TSH and positive correlations with free and total T3 and T4 levels, supporting a close association between trophoblastic activity and thyroid function. These findings suggest that thyroid dysfunction may be particularly relevant in women with complete hydatidiform mole or markedly elevated serum β-hCG concentrations; however, larger multicentric studies with adjustment for potential confounding factors and longitudinal follow-up are warranted to clarify the clinical significance of these associations.

PMID 42763703
Read full article →
PubMedCureus2026-09-20

Recurrent Deep (Aggressive) Angiomyxoma of the Pelvis: Serial MRI Documentation of Sustained Complete Radiologic Response During Eight Years of Gonadotropin-Releasing Hormone (GnRH) Agonist Therapy.

Fevereiro Beatriz B, Fonseca Ricardo R, Cunha Teresa Margarida TM

Deep (aggressive) angiomyxoma is a rare mesenchymal tumor that primarily affects premenopausal women and is frequently misdiagnosed because of its deep pelvic location, indolent growth, and nonspecific clinical presentation. It is typically multicompartmental and demonstrates a characteristic laminated ("swirled") appearance on T2-weighted magnetic resonance imaging (MRI), reflecting alternating myxoid and fibrous stromal components. Local recurrence is common after surgical resection, making long-term imaging surveillance essential. Tumor expression of estrogen and progesterone receptors provides a biological rationale for hormonal therapy. We report a case of recurrent pelvic deep (aggressive) angiomyxoma in a 45-year-old woman who achieved complete and sustained radiologic remission documented by serial MRI throughout 8 years of continuous gonadotropin-releasing hormone (GnRH) agonist therapy. This uncommon long-term outcome highlights both the potential for durable disease control with hormonal therapy in deep (aggressive) angiomyxoma and the value of MRI for longitudinal assessment of treatment response.

PMID 42763626
Read full article →
PubMedCureus2026-09-20

Histomorphological and Immunohistochemical Profile of Malignant Breast Lesions in a Tertiary Care Center of Central India: A Cross-Sectional Study.

Himani Himani H, Jain Atul A, Agarwal Shikha S, Gangwani Amar A

Breast carcinoma is a heterogeneous malignancy with variable histomorphological patterns and immunohistochemical profiles. Evaluation of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) expression provides important prognostic and predictive information for treatment planning. Ki-67 was not evaluated in the present study; therefore, the reported immunohistochemical subgroups were based only on ER, PR, and HER2/neu expression. This study aimed to assess the histomorphological and immunohistochemical profile of malignant breast lesions in a tertiary care center in Central India. This cross-sectional observational study included 84 patients with histopathologically confirmed malignant breast lesions. Tumors were classified according to standard histopathological criteria and graded using the Nottingham modification of the Bloom-Richardson system. Immunohistochemistry was performed for ER, PR, and HER2/neu. Molecular subtypes were assigned based on ER, PR, and HER2/neu expression. The most common age group was 41-50 years (n = 39, 46.4%). Invasive ductal carcinoma, not otherwise specified, accounted for 95.2% (80/84) of cases. Grade III tumors were observed in 58.3% (49/84), and lymph node metastasis was present in 58.3% (49/84). ER, PR, and HER2/neu positivity were observed in 59.5%, 53.6%, and 29.8% of cases, respectively. The hormone receptor (HR)-positive/HER2-negative subgroup was the most common (59.5%), followed by HR-positive/HER2-positive (17.9%), HR-negative/HER2-positive (11.9%), and triple-negative (10.7%) subgroups. On descriptive analysis, HR positivity decreased with increasing tumor grade and nodal positivity, whereas HER2/neu positivity increased. Histopathological evaluation combined with ER, PR, and HER2/neu immunohistochemistry provides important information for tumor classification, prognostic assessment, and therapeutic decision-making in breast carcinoma. Routine integrated reporting is essential for individualized management of malignant breast lesions.

PMID 42763585
Read full article →
PubMedUrologie (Heidelberg, Germany)2026-09-20

[Gender-affirming hormone therapy: state of the art].

Bischoff Jenny J

Gender incongruence affects approximately 0.6% of the population in Germany and, when accompanied by significant psychological distress, may constitute an indication for gender-affirming hormone therapy (GAHT). The increasing diversity of gender identity has led to a more individualized approach to hormone therapy. The decision to initiate treatment is based on the expected reduction in gender-related dysphoria due to hormonal treatment. Treatment is carried out in accordance with guidelines and is tailored to the wishes and goals of the person seeking treatment. Various estradiol preparations and antiandrogenic substances can be used to achieve feminization. Masculinizing therapy relies primarily on testosterone. For non-binary individuals, GAHT is usually administered at lower doses and typically focuses on specific aspects of gender alignment. The therapeutic effects usually develop slowly but can be irreversible and significant. Risks should be assessed in advance, and patients should be informed about potential adverse effects. Monitoring and adjustment of treatment take place at specified regular intervals. Adjustments and support throughout the course of treatment-ranging from fertility preservation to cancer screening-are key components of comprehensive care in patients undergoing GAHT. Although the evidence regarding GAHT has improved significantly in recent years, large-scale studies are still lacking for many aspects.

PMID 42763335
Read full article →
PubMedCureus2026-09-20

Noncanonical Splice Site Disruption: +4 Intronic Variant in Phosphate-Regulating Endopeptidase Homolog, X-linked (PHEX Gene) Supported by In Silico Analysis in X-linked Hypophosphatemic Rickets.

Panqueba Arias Carlos F CF, Rojas Rodriguez Ingry K IK, Quero Rossi I RI, Baez Cielo C CC

X-linked hypophosphatemic rickets (XLH) is the most common inherited cause of renal phosphate wasting. It is typically caused by pathogenic variants in the phosphate-regulating endopeptidase homolog, X-linked (PHEX gene), which lead to increased levels of fibroblast growth factor 23 (FGF23). However, noncanonical intronic variants represent a significant diagnostic challenge, as they may not be detected by conventional genetic studies and require interpretation supported by bioinformatic tools. We present the case of a pediatric patient with postnatal short stature and progressive genu varum. Biochemical studies revealed hypophosphatemia with reduced tubular reabsorption of phosphate, while calcium, parathyroid hormone (PTH), and vitamin D levels were within normal ranges. Radiological findings were consistent with rickets. Initial clinical exome sequencing was negative. Subsequently, a targeted gene panel identified a previously unreported intronic variant in the PHEX gene (c.1768+4dup; chrX:22,219,105 T>TA). In silico analysis using SpliceAI demonstrated a high probability of donor splice site loss (DS_DL = 0.80), while Pangolin predicted a splice-disrupting effect (score = 0.72); collectively, these findings support a deleterious effect on mRNA splicing. This case highlights the importance of integrating clinical, biochemical, genetic, and computational data for the interpretation of noncanonical intronic variants, expanding the mutational spectrum described for PHEX in XLH.

PMID 42763725
Read full article →
PubMedJournal of pediatric endocrinology & metabolism : JPEM2026-09-20

Anti-Müllerian hormone levels in girls with precocious puberty.

Hepokur Merve Nur MN, Çamaş Aşan Önder AÖ, Taniş Gözde G, Çiçek Burçin B et al.

We aimed to evaluate the relationship between anti-Müllerian hormone (AMH) levels in cases of central precocious puberty (CPP), premature adrenarche (PA), and isolated premature thelarche (IPT) and those of healthy controls (HC). A total of 153 girls (40 PA, 39 CPP, 39 IPT, and 35 HC) were included in the study. AMH levels were assessed using the ELISA method. The mean age of all participants was 7.19 ± 0.63 (5.0-8.0) years. Height SDS was higher in the puberty and puberty variant groups compared with the healthy group. This difference was found to be statistically significant between the CPP and HC groups. Obesity was present in 20 of all participants (13 %). AMH levels were 0.125 ± 0.154, 0.086 ± 0.072, 0.084 ± 0.074, and 0.069 ± ;0.060 ng/mL in PA, PT, CPP, and HC groups, respectively. Although AMH levels were higher in the PA group, there was no statistically significant difference among the four groups. A weak negative correlation was found between AMH levels and BMI SDS (body mass index standard deviation score). AMH levels do not differ between prepubertal girls and those diagnosed with central precocious puberty or a variant of puberty of the same age.

PMID 42763793
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about recombinant human growth hormone